Calcineurin Inhibitor-Free Immunosuppression Using Everolimus (Certican) in Maintenance Heart Transplant Recipients: 6 Months' Follow-up

Preliminary data suggest that CNI-free immunosuppression using everolimus is safe, with excellent efficacy in maintenance heart transplant recipients. Arterial hypertension and renal function improved significantly. CNI-induced side effects such as tremor, peripheral edema, hirsutism, and gingival hyperplasia markedly improved in most patients.